Hide filtersShow filters × Close Bryan, Garnier & Co acts as Joint Global Coordinator & Joint Bookrunner on Egetis Therapeutics’ Nasdaq Stockholm SEK 210 million Follow-on Offering Bryan, Garnier & Co acts as Sole Financial Advisor to Selfapy, one of the leading providers in digital therapeutics for mental health disorders in Germany, on its growth financing from strategic investor Medice Arzneimittel and existing shareholders Bryan, Garnier & Co acts as Sole Bookrunner on Oncodesign Precision Medicine’s EUR 8 million Follow-on Offering & IPO on Euronext Growth Paris Bryan, Garnier & Co acts as Sole Financial Advisor to XVIVO on the acquisition of the Machine & Perfusion division from Avionord S.r.l. Bryan, Garnier & Co acts as Joint Global Coordinator & Joint Bookrunner on Nicox’ Euronext Paris EUR 10 million Follow-on Offering & Warrants issuance Bryan, Garnier & Co acts as Joint Bookrunner on Valneva’s Nasdaq and Euronext Paris EUR 102.9 million Follow-on Offering Bryan, Garnier & Co acts as Sole Global Coordinator and Joint Bookrunner on Abivax’s EUR 49 million Cross-over Financing Bryan, Garnier & Co acts as Sole Financial Advisor to Ganymed Robotics, a developer of computer vision software and robotics technologies for orthopedic surgeons, on its first €21 million closing of its oversubscribed Fundraising Bryan, Garnier & Co acts as Sole Financial Advisor to Oncodesign on the sale of its CRO activities to Elyan Partners for €100m and the concomitant spin-off of its Biotech/AI activities Bryan, Garnier & Co acts as Sole Global Coordinator & Sole Bookrunner on GeNeuro EUR 7.7 million Follow-On Offering Bryan, Garnier & Co acts as Sole Financial Advisor to the shareholders of Grundium Oy on the sale of a majority stake to EW Healthcare Partners Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner on Aelis Farma’s Euronext Paris EUR 25m Initial Public Offering
